Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 24, 2023

Ibrutinib Plus Rituximab Is Highly Effective in Patients With CLL With Steroid-Refractory and Relapsed Autoimmune Cytopenias



Additional Info

Disclosure statements are available on the authors' profiles:

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
Leukemia 2023 May 18;[EPub Ahead of Print], E Nikitin, M Kislova, D Morozov, V Belyakova, A Suvorova, J Sveshnikova, G Vyscub, I Matveeva, M Shirokova, A Shipaeva, T Klitochenko, P Makarovskaya, E Dmitrieva, B Biderman, A Sudarikov, T Obukhova, O Samoilova, K Kaplanov, T Konstantinova, O Mayorova, I Poddubnaya, V Ptushkin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading